Eupraxia Pharmaceuticals (EPRX) Depreciation & Amortization (CF) (2023 - 2025)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Depreciation & Amortization (CF) of $72806.0 for Q4 2025, up 33.56% year-over-year from $54512.0 in Q4 2024, and up 15.58% quarter-over-quarter from $62993.0 in Q3 2025.
Eupraxia Pharmaceuticals (EPRX) Depreciation & Amortization (CF) (2023 - 2025) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Depreciation & Amortization (CF) for 3 consecutive years, with $72806.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) rose 33.56% year-over-year to $72806.0; the TTM figure through Mar 2026 stood at $191230.0 (up 5.78% YoY), while the FY2025 annual figure was $237717.0, up 38.43% from the prior year.
- Depreciation & Amortization (CF) grew to $72806.0 in Q4 2025 per EPRX's latest filing, from $62993.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $72806.0 in Q4 2025 and bottomed at $37418.0 in Q1 2024.
- Historically, Depreciation & Amortization (CF) has averaged $47080.2 across 3 years, with a median of $41631.5 in 2023.
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) declined 2.47% — and 2025, when it surged 66.83%.
- Eupraxia Pharmaceuticals' Depreciation & Amortization (CF) stood at $41233.0 in 2023, then surged by 32.2% to $54512.0 in 2024, then soared by 33.56% to $72806.0 in 2025.
- Business Quant data shows EPRX's Depreciation & Amortization (CF) at $72806.0 in Q4 2025, $62993.0 in Q3 2025, and $55431.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 72,806.00 |
| Dec 31, 2025 | 72,806.00 |
| Sep 30, 2025 | 62,993.00 |
| Sep 30, 2025 | 62,993.00 |
| Jun 30, 2025 | 55,431.00 |
| Jun 30, 2025 | 55,431.00 |
| Mar 31, 2025 | 46,487.00 |
| Mar 31, 2025 | 46,487.00 |
| Dec 31, 2024 | 54,512.00 |
| Dec 31, 2024 | 54,512.00 |
| Sep 30, 2024 | 37,759.00 |
| Sep 30, 2024 | 37,759.00 |
| Jun 30, 2024 | 42,030.00 |
| Jun 30, 2024 | 42,030.00 |
| Mar 31, 2024 | 37,418.00 |
| Mar 31, 2024 | 37,418.00 |
| Dec 31, 2023 | 41,233.00 |
| Dec 31, 2023 | 41,233.00 |
| Sep 30, 2023 | 38,716.00 |
| Sep 30, 2023 | 38,716.00 |